By Davit Kirakosyan Wolfe Research downgraded World Wrestling Entertainment (NYSE:WWE) to Peer Perform from Outperform and removed the $111 price target. Shares are up about 25%...
Edwards Lifesciences (EW) reported Q4 EPS of $0.64, $0.03 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.35 billion versus the consensus estimate...
Strong U.S. dollar impacted its aortic valve sales Despite sliding this year, Edwards Life Sciences stock is overvalued Earnings dented by rising costs, COVID restraints, and...
A heavy earnings week is always a busy time for the markets, but is “busy” really the word to describe the past week?First, Let’s Talk About TwitterWell, the...
There are plenty of people out there that always say “I’m waiting for a big market dip to get fully invested in the market,” yet when the dip actually occurs,...
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.
|Average||88.11 (+7.29% Upside)|
|No. of Analysts||19|